Differences

This shows you the differences between two versions of the page.

--- home:protocol:olmesartan [12.03.2018] – [Cardiovascular disease] sallieq
+++ home:protocol:olmesartan [04.20.2019] – [Other beneficial effects] sallieq
@@ Line 123: / Line 123: @@
   * inhibit liver fibrosis and aid liver healing(({{pubmed>long:12871826}}))
   * reduce insulin resistance in rats(({{pubmed>long:15127887}}))
-  * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed>long:23775504}}))
+  * 6 mg/kg olmesartan reduces the inflammatory process and periodontal bone loss in rats(({{pubmed>long:23775504}}))
   * protect the mitochondria from age-associated damage from oxidation(({{pubmed>long:12709417}}))
   * play a protective role against proliferative diabetic retinopathy (({{pubmed>long:17560613}}))
@@ Line 170: / Line 171: @@
   * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>long:23154587}}))
   * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed>long:22149003}}))
-  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:3862195}}))
+  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}}))
   * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects  (({{pubmed>long:24842388}}))

home/protocol/olmesartan.txt · Last modified: 09.14.2022 by 127.0.0.1